TY - JOUR
AU - Accorsi Buttini, Eugenia
AU - Farina, Mirko
AU - Lorenzi, Luisa
AU - Polverelli, Nicola
AU - Radici, Vera
AU - Morello, Enrico
AU - Colnaghi, Federica
AU - Almici, Camillo
AU - Ferrari, Emilio
AU - Bianchetti, Andrea
AU - Leoni, Alessandro
AU - Re, Federica
AU - Bosio, Katia
AU - Bernardi, Simona
AU - Malagola, Michele
AU - Re, Alessandro
AU - Russo, Domenico
PY - 2023
M3 - Case Report
TI - High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review
JO - Frontiers in Oncology
UR - https://www.frontiersin.org/articles/10.3389/fonc.2023.1036455
VL - 13
SN - 2234-943X
N2 - BackgroundChimeric antigen receptor (CAR) T-cell therapy represents the most advanced immunotherapy against relapsed/refractory B cell malignancies. While cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are distinctive, known CAR T-cell acute adverse events, hematological toxicity has been increasingly reported. Cytopenia following CAR T-cell treatment is attributed in most cases to lymphodepletion regimens, bridging chemotherapy, or radiotherapy. However, when cytopenia becomes prolonged, the development of myelodysplastic syndrome (MDS) should be considered.Case presentationWe report a case of high risk (HR)-MDS following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma. Eight months after CAR T-cell infusion, the blood count showed progressive, worsening cytopenia and the bone marrow biopsy revealed multilineage dysplasia without excess of blasts associated with chromosome 7 deletion and RUNX1 mutation. Next generation sequencing analysis, retrospectively performed on stored samples, showed a germ line CSF3R mutation, CEBPA clonal hematopoiesis, but no RUNX1 lesion.ConclusionWe describe a case of HR-MDS, with deletion of chromosome 7 and acquisition of RUNX1 mutation, developing after CAR T-cell therapy in a patient with clonal hematopoiesis (CH). Previous chemotherapy favored MDS onset; however, we could not exclude the fact that the impairment of immunosurveillance related to either lymphodepletion or CAR T-cell infusion may play a role in MDS development. Thus, we designed a multicenter prospective study (ClonHema-CAR-T-Study) to investigate if cytopenia after CAR T-cell treatment may be due to underling CH as well as the presence of secondary myeloid malignancies.
ER -